Floatz logo

DEXAMETHASONE

Adult Acute Minimally Differentiated Myeloid Leukemia (M0)

Steven E. CoutreSmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Acute Minimally Differentiated Myeloid Leukemia (M0) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Northwestern University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →